Skip to main content
Top
Published in: Medical Oncology 8/2019

01-08-2019 | Ovarian Cancer | Review Article

Functional coding and non-coding variants in human BRCA1 gene and their use in genetic screening

Authors: Gulten Tuncel, Mahmut Çerkez Ergören

Published in: Medical Oncology | Issue 8/2019

Login to get access

Abstract

BRCA1 is involved in double-strand DNA damage repair pathways, and mutations in the gene are associated with hereditary breast and ovarian cancers. With great help of the development of high-throughput DNA sequencing techniques numerous single-nucleotide polymorphisms (SNPs) and insertion deletion (Indel) mutations are detected on both coding and non-coding/regulatory regions of the BRCA1. Mutations may cause pathogenic or benign changes on the protein function or affect its expression. In the last decade, use of genetic screening tests to detect mutations on such genes has become greatly popular. However, it is very important to know the effect of the detected mutations, which is mostly possible by the use of predictive softwares, and also the related family history to be able to correctly analyse the screening results and to inform the patient. Therefore, use of in silico and in vitro techniques to score the pathogenicity of detected variants on genes like BRCA1 is now of great importance. Otherwise, results obtained from screening tests and family history cannot be analysed precisely.
Literature
1.
go back to reference Campbell CD, Eichler EE. Properties and rates of germline mutations in humans. Trends Genet. 2013;29(10):575–84.CrossRef Campbell CD, Eichler EE. Properties and rates of germline mutations in humans. Trends Genet. 2013;29(10):575–84.CrossRef
2.
go back to reference Griffiths AJ, et al. Somatic versus germinal mutation. An introduction to genetic analysis. Stuttgart: W. H. Freeman; 2000. Griffiths AJ, et al. Somatic versus germinal mutation. An introduction to genetic analysis. Stuttgart: W. H. Freeman; 2000.
3.
go back to reference Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell. 2010;1(2):117–23.CrossRef Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell. 2010;1(2):117–23.CrossRef
4.
go back to reference Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–59.CrossRef Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–59.CrossRef
5.
go back to reference Lippi G, Mattiuzzi C, Montagnana M. BRCA population screening for predicting breast cancer: for or against? Ann Transl Med. 2017;5:13.CrossRef Lippi G, Mattiuzzi C, Montagnana M. BRCA population screening for predicting breast cancer: for or against? Ann Transl Med. 2017;5:13.CrossRef
9.
go back to reference Smigielski EM, et al. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 2000;28(1):352–5.CrossRef Smigielski EM, et al. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 2000;28(1):352–5.CrossRef
10.
go back to reference Thery JC, et al. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet. 2011;19(10):1052–8.CrossRef Thery JC, et al. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet. 2011;19(10):1052–8.CrossRef
11.
go back to reference Esposito MV, et al. A novel pathogenic BRCA1 splicing variant produces partial intron retention in the mature messenger RNA. Int J Mol Sci. 2016;17(12):2145.CrossRef Esposito MV, et al. A novel pathogenic BRCA1 splicing variant produces partial intron retention in the mature messenger RNA. Int J Mol Sci. 2016;17(12):2145.CrossRef
12.
go back to reference López de Silanes I, Paz Quesada M, Esteller M. Aberrant regulation of messenger RNA 3 and M. Esteller, r Intron Retention. Cell Oncol. 2007;29(1):1–17.PubMedPubMedCentral López de Silanes I, Paz Quesada M, Esteller M. Aberrant regulation of messenger RNA 3 and M. Esteller, r Intron Retention. Cell Oncol. 2007;29(1):1–17.PubMedPubMedCentral
13.
go back to reference Singh P, et al. Global changes in processing of mRNA 3′ untranslated regions characterize clinically distinct cancer subtypes. Cancer Res. 2009;69(24):9422–30.CrossRef Singh P, et al. Global changes in processing of mRNA 3′ untranslated regions characterize clinically distinct cancer subtypes. Cancer Res. 2009;69(24):9422–30.CrossRef
14.
go back to reference Mao G, Pan X, Gu L. Evidence that a mutation in the MLH1 3′-untranslated region confers a mutator phenotype and mismatch repair deficiency in patients with relapsed leukemia. J Biol Chem. 2008;283(6):3211–6.CrossRef Mao G, Pan X, Gu L. Evidence that a mutation in the MLH1 3′-untranslated region confers a mutator phenotype and mismatch repair deficiency in patients with relapsed leukemia. J Biol Chem. 2008;283(6):3211–6.CrossRef
15.
go back to reference Karbassi I, et al. A standardized DNA variant scoring system for pathogenicity assessments in mendelian disorders. Hum Mutat. 2016;37(1):127–34.CrossRef Karbassi I, et al. A standardized DNA variant scoring system for pathogenicity assessments in mendelian disorders. Hum Mutat. 2016;37(1):127–34.CrossRef
16.
go back to reference Dorairaj JJ, et al. A germline mutation in the BRCA1 3′ UTR predicts stage IV breast cancer. BMC Cancer. 2014;14:421.CrossRef Dorairaj JJ, et al. A germline mutation in the BRCA1 3′ UTR predicts stage IV breast cancer. BMC Cancer. 2014;14:421.CrossRef
17.
go back to reference Brewster BL, et al. Identification of fifteen novel germline variants in the BRCA1 3′ UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat. 2012;33(12):1665–75.CrossRef Brewster BL, et al. Identification of fifteen novel germline variants in the BRCA1 3′ UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat. 2012;33(12):1665–75.CrossRef
18.
go back to reference Gochhait S, et al. Implication of BRCA2-26G>A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res. 2007;9(5):R71.CrossRef Gochhait S, et al. Implication of BRCA2-26G>A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res. 2007;9(5):R71.CrossRef
19.
go back to reference Evans DGR, et al. A dominantly inherited 5′ UTR variant causing methylation-associated silencing of BRCA1 as a cause of breast and ovarian cancer. Am J Hum Genet. 2018;103(2):213–20.CrossRef Evans DGR, et al. A dominantly inherited 5′ UTR variant causing methylation-associated silencing of BRCA1 as a cause of breast and ovarian cancer. Am J Hum Genet. 2018;103(2):213–20.CrossRef
20.
go back to reference Sim NL, et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452–7.CrossRef Sim NL, et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452–7.CrossRef
21.
go back to reference Zick A, et al. A BRCA1 frame shift mutation in women of Kurdish Jewish descent. Open Med J. 2015;2:31–6.CrossRef Zick A, et al. A BRCA1 frame shift mutation in women of Kurdish Jewish descent. Open Med J. 2015;2:31–6.CrossRef
22.
go back to reference Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol. 2010;34(2):134–44.CrossRef Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol. 2010;34(2):134–44.CrossRef
23.
go back to reference Kaplan F. Tay–Sachs disease carrier screening: a model for prevention of genetic disease. Genet Test. 1998;2(4):271–92.CrossRef Kaplan F. Tay–Sachs disease carrier screening: a model for prevention of genetic disease. Genet Test. 1998;2(4):271–92.CrossRef
24.
go back to reference Bozkurt G. Results from the north cyprus thalassemia prevention program. Hemoglobin. 2007;31(2):257–64.CrossRef Bozkurt G. Results from the north cyprus thalassemia prevention program. Hemoglobin. 2007;31(2):257–64.CrossRef
25.
go back to reference Lynch J, Venne V, Berse B. Genetic tests to identify risk for breast cancer. Semin Oncol Nurs. 2015;31(2):100–7.CrossRef Lynch J, Venne V, Berse B. Genetic tests to identify risk for breast cancer. Semin Oncol Nurs. 2015;31(2):100–7.CrossRef
26.
go back to reference Cline MS, et al. BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14(12):e1007752.CrossRef Cline MS, et al. BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14(12):e1007752.CrossRef
Metadata
Title
Functional coding and non-coding variants in human BRCA1 gene and their use in genetic screening
Authors
Gulten Tuncel
Mahmut Çerkez Ergören
Publication date
01-08-2019
Publisher
Springer US
Published in
Medical Oncology / Issue 8/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-019-1294-9

Other articles of this Issue 8/2019

Medical Oncology 8/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.